ArticleFrontiers in oncology2025
Impact of breast cancer genetic testing in Brazilian patients: insights from the MAGENTA study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer is the most prevalent cancer among women in Brazil, with up to 10% of cases linked to hereditary factors. Genetic testing and counseling are critical for identifying hereditary breast cancer risk, guiding treatment decisions, and preventing cancer in high-risk populations. Objectives: This study aimed to analyze the experience, perspectives, and access barriers to breast cancer genetic testing in the Brazilian respondents of the Multinational Survey Study Assessing GENetic Testing and Counseling Among Patients with Breast Cancer (MAGENTA) study. Methods: A 38-multiple-choice question, branched survey was distributed by patient advocacy agencies to collect sociodemographic and patient-perspective data about their experience with breast cancer genetic testing. A multivariate analysis was conducted to explore the association between sociodemographic variables and the genetic testing status. Results: 207 breast cancer patients completed the survey. In this cohort, the rates of genetic testing and counseling were 81.6% and 60.4%, respectively. 66.7% of respondents reported a high or advanced educational level. Notably, 71.7% of patients reported that genetic testing changed their treatment plans, and 77.1% of those who took the test were willing to test their familiars. In addition, 98.7% stated they did not regret undergoing genetic testing. Higher income was independently associated with higher odds of undergoing genetic testing (OR: 4.43 [95% CI: 1.64;13.11]; p = 0.0011), while having more than 50 years-old was associated with a lower odds of undergoing testing (OR: 0.21 [95% CI: 0.08;0.56]; p=0.0018). Barriers such as costs and limited awareness were prominent, with 89% of patients in Brazil reporting low awareness of genetic testing prior to their diagnosis. Conclusions: The survey respondents in Brazil comprised a highly educated and financially secure group of patients. Although not generalizable to the entire Brazilian population, our results revealed that even in a highly educated and well-informed cohort there is a strong association between age and income level with genetic testing. These findings expose the real-world challenges for increasing genetic testing coverage in Brazil, where testing is only warranted in the private health system, highlighting the need for health policies to increase test availability for lower income brackets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.